Released Nov 10, 2021, before the open
10-Q filed Nov 10, 2021, 41 days after period end · 0001785530-21-000054
Q3 2021 · 10-Q
Revenue—
Net Income-$13.76M-$13.76M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.51-$0.51 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$13,795,000N/M
Operating Cash Flowderived-$12,417,000N/M
Free Cash Flowderived-$12,519,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Net Income | -$13.76M | -$6.07M |
| EPS Diluted | -$0.51 | -$6.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR